| 王 亮,王 明,李兴德,朱中成,何 翔,刘春燕.食管癌组织CDC25B的表达与临床病理参数及放疗敏感性的关系研究[J].现代生物医学进展英文版,2020,(19):3761-3765. |
| 食管癌组织CDC25B的表达与临床病理参数及放疗敏感性的关系研究 |
| The Relationship between the Expression of CDC25B and Clinicopathological Parameters and Radiosensitivity in Esophageal Cancer |
| Received:February 27, 2020 Revised:March 22, 2020 |
| DOI：10.13241/j.cnki.pmb.2020.19.035 |
| 中文关键词: 食管癌 细胞分裂周期蛋白25B 临床病理参数 放疗 敏感 抗拒 |
| 英文关键词: Esophageal cancer CDC25B Clinicopathological parameters Radiotherapy Sensitivity Resistance |
| 基金项目:河北省医学科学研究重点课题计划项目(20181137)；沧州市2017年重点研发计划项目（172302087） |
| Author Name | Affiliation | E-mail | | WANG Liang | First Department of Gastroenterology, Cangzhou Central Hospital of Hebei Province, Cangzhou, Hebei, 061001, China | wangliang33883@163.com | | WANG Ming | Department of Radiotherapy, Cangzhou Central Hospital of Hebei Province, Cangzhou, Hebei, 061001, China | | | LI Xing-de | Department of Radiotherapy, Cangzhou Central Hospital of Hebei Province, Cangzhou, Hebei, 061001, China | | | ZHU Zhong-cheng | Department of Radiotherapy, Cangzhou Central Hospital of Hebei Province, Cangzhou, Hebei, 061001, China | | | HE Xiang | Department of CT Diagnostics, Cangzhou Central Hospital of Hebei Province, Cangzhou, Hebei, 061001, China | | | LIU Chun-yan | Department of Pathology, People's Hospital of Hebei Medical University, Shijiazhuang, Hebei, 050001, China | |
|
| Hits: 704 |
| Download times: 425 |
| 中文摘要: |
| 摘要 目的：探讨食管癌组织中细胞分裂周期蛋白25B （CDC25B）表达特点，分析其与食管癌临床病理参数和放疗敏感性的关系。方法：选择2015年1月至2018年1月我院收集的60例食管癌患者癌组织、癌旁组织的石蜡标本，采用免疫组化法检测食管癌组织和癌旁组织中CDC25B表达，分析CDC25B表达与食管癌临床病理参数的关系。所有患者均接受放疗或放化疗治疗，观察不同疗效患者CDC25B表达差异，分析CDC25B对食管癌放疗敏感性的预测价值。结果：食管癌组织中CDC25B阳性表达率高于癌旁组织（P<0.05）。CDC25B阳性表达与食管癌分化程度、TNM分期、淋巴结转移有关（P<0.05）。放疗敏感组CDC25B阳性表达率低于放疗抗拒组（P<0.05）。CDC25B预测食管癌放疗敏感性的曲线下面积（AUC）为0.718（95%CI：0.580~0.856），灵敏度为60%，特异度为68%。结论：食管癌患者CDC25B表达上调，CDC25B阳性表达与食管癌分化程度、TNM分期、淋巴结转移恶性侵袭行为有关，CDC25B可作为食管癌放疗敏感性评估的辅助指标。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the expression of cyclin 25B (CDC25B) in esophageal cancer and analyze its relationship with clinicopathological parameters and radiosensitivity. Methods: From January 2015 to January 2018, 60 paraffin specimens of esophageal cancer tissues and paracancerous tissues were collected from our hospital. The expression of CDC25B was detected by immunohistochemistry, the relationship between the expression of CDC25B and the clinicopathological parameters of esophageal cancer were analyzed. All patients received radiotherapy or radiotherapy combined with chemotherapy. The expression of CDC25B in different radiotherapy groups was observed, and the predictive value of CDC25B on radiotherapy sensitivity of esophageal cancer was analyzed. Results: The positive expression rate of CDC25B in esophageal carcinoma was higher than that in adjacent tissues (P<0.05). The positive expression of CDC25B was related to the differentiation, TNM stage and lymph node metastasis (P<0.05). The positive expression rate of CDC25B in radiotherapy sensitive group was lower than that in radiotherapy resistant group (P<0.05). The AUC of CDC25B was 0.718 (95% CI: 0.580-0.856), the sensitivity was 60%, and the specificity was 68%. Conclusion: The expression of CDC25B is up-regulated in patients with esophageal cancer, and the positive expression of CDC25B is related to the differentiation degree, TNM stage and lymph node metastasis. CDC25B can be used as an auxiliary index to evaluate the radiosensitivity of esophageal cancer. |
|
View Full Text
View/Add Comment Download reader |
| Close |
|
|
|
